Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 12

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 12
---
 shares of STAAR common stock through a bank,
broker, trust, or other nominee and you wish to exercise appraisal rights, you may make a written demand for appraisal in your own name, but you must satisfy the conditions set forth above and your written demand must also reasonably identify the
holder of record of the shares of STAAR common stock for which demand is made, be accompanied by documentary evidence of

-4-

your beneficial ownership of stock (such as a brokerage or securities account statement containing such information or a letter from a broker or other record holder of such shares confirming such information) and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provide an address at which you consent to receive notices given by the Surviving Corporation under Section 262 and to be set forth on the verified list required by Section 262(f) of the DGCL. Regulatory Approvals Required for the Merger The consummation of the Merger is subject to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (which this proxy statement refers to as the “HSR Act”). A transaction notifiable under the HSR Act may not be completed until the expiration or termination of a 30-daywaiting period following the parties’ filings of their HSR Act notification and report forms. If the Federal Trade Commission (which this proxy statement refers to as the “FTC”) or the Antitrust Division of the Department of Justice (which this proxy statement refers to as the “DOJ”) issues a request for additional information and documentary materials (which this proxy statement refers to as a “Second Request”) prior to the expiration of the initial waiting period, the parties must observe a second 30-daywaiting period, which would begin to run only after the parties have substantially complied with the Second Request, unless the waiting period is terminated earlier or the parties otherwise agree to extend the waiting period. The parties intend to make the filings required under the HSR Act on or before September 2, 2025, the deadline under the Merger Agreement. In addition to clearance under the HSR Act, the consummation of the Merger is also subject to the receipt of regulatory approvals in certain other jurisdictions, including antitrust approvals in China and Japan among others, as set forth in greater detail in the section of this summary titled “ —Conditions to the Closing of the Merger” and “ The Merger Agreement—Conditions to